Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

巴塞尔，2024年7月9日-罗氏（SIX:RO，ROG；OTCQX:RHHBY）今天宣布，其Accu-Chek SmartGuide®连续血糖监测（CGM）解决方案已获得CE标志。这一重要里程碑为18岁以上的1型和2型糖尿病患者通过灵活的胰岛素治疗提供解决方案铺平了道路。

“Maintaining optimal blood glucose levels and preventing adverse glycaemic episodes remains a complex task for people living with diabetes, often necessitating up to 180 therapy decisions a day2,” said Matt Sause, CEO of Roche Diagnostics. “Our novel CGM solution with its predictive algorithms will help address significant unmet needs associated with diabetes management, empowering users to take control of their condition and live better and healthier lives.” Despite CGM technology's demonstrated positive impact on glycaemic control,3 a significant proportion of people living with diabetes still do not meet glycaemic targets - even when using a CGM system.4 Moreover, they typically encounter an average of two hypoglycaemic episodes a week, with 1-2 of these being severe enough to require medical intervention each year.5 Notably, nighttime hypoglycaemia is associated with reduced quality of life, increased anxiety, and fear.

罗氏诊断公司（Roche Diagnostics）首席执行官马特·索斯（Matt Sause）说：“维持最佳血糖水平和预防不良血糖发作对于糖尿病患者来说仍然是一项复杂的任务，通常每天需要多达180个治疗决定。”。“我们的新型CGM解决方案及其预测算法将有助于解决与糖尿病管理相关的重大未满足需求，使用户能够控制自己的病情，过上更好、更健康的生活。”尽管CGM技术对血糖控制产生了积极影响，但3即使使用CGM系统，仍有相当一部分糖尿病患者仍未达到血糖目标。此外，他们通常每周平均会发生两次低血糖事件，其中1-2次严重到每年都需要医疗干预。值得注意的是，夜间低血糖与生活质量下降，焦虑和恐惧增加有关。

The persistent fear of hypoglycaemia, hypoglycaemia unawareness, sleep disruption, and.

持续的低血糖恐惧，低血糖无意识，睡眠中断和。